Search results

Skip to results

Type

Status

Last updated

Showing 1 to 3 of 3 results for ponesimod

  1. Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)

    Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA767

  2. Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)

    Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    15 April 2025
    View recommendations

    Sections for TA1053

  3. Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]

    In development [GID-TA10977] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development